Is Vertex Pharmaceuticals a Buy?
In the past year, Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price has fallen by 24%. That is a particularly disappointing performance, especially considering the S&P 500 rose by 40% over the same period.
However, there is a silver lining here: Vertex stock now looks amazingly cheap, trading at a price-to-earnings (P/E) ratio of 20, while the average biotech stock is valued at a P/E ratio of 31. So should you buy Vertex stock on the dip?
Image source: Getty Images.
Source Fool.com
